Hypoattenuated leaflet thickening

1. Tirzepatide decreases hypoattenuated leaflet thickening in obese patients undergoing transfemoral TAVR, assessed at 6 months (8.4% vs 21.6%; p = 0.002).

   “tirzepatide therapy significantly reduced HALT incidence (8.4% vs 21.6%, p = 0.002)”

   Human trialin obese patients undergoing transfemoral TAVR, assessed at 6 months6 months

   Tirzepatide therapy reduces subclinical leaflet thrombosis and paravalvular leak after transcatheter aortic valve replacement in obese patients: The TAVR-MET trial

   Cardiovascular revascularization medicine : including molecular interventions·Mar 23, 2026

More on Tirzepatide

1. Hypoattenuated leaflet thickening was not clearly linked with mortality in humans following transcatheter aortic valve implantation (HR 0.86, 95% CI 0.202–3.687; P = 0.84).

   “HALT was linked with greater WMH burden, but did not carry an increased risk of cognitive decline or mortality over a 3.1-year follow-up”

   Humansfollowing transcatheter aortic valve implantation3.1 years

   Subclinical leaflet thrombosis after transcatheter aortic valve implantation is associated with silent brain injury on brain magnetic resonance imaging

   European heart journal. Cardiovascular Imaging·Sep 29, 2022

1. Hypoattenuated leaflet thickening is associated with new white matter hyperintensity volume in humans following transcatheter aortic valve implantation (β 0.72, 95% CI 0.2–1.39; P = 0.009).

   “In uni- and multivariate analysis, HALT was associated with new WMH volume (beta: 0.72; 95%CI: 0.2-1.39; P = 0.009).”

   Humansfollowing transcatheter aortic valve implantationbrain6 monthsn = 91

   Subclinical leaflet thrombosis after transcatheter aortic valve implantation is associated with silent brain injury on brain magnetic resonance imaging

   European heart journal. Cardiovascular Imaging·Sep 29, 2022

More on New white matter hyperintensity volume